News|Articles|April 22, 2024
Utilizing COAs Across Different Therapeutic Areas
Author(s)Andy Studna, Senior Editor
In part 1 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA touches on how the use of clinical outcome assessments differs across therapeutic areas.
Advertisement
ACT: How does the utilization of clinical outcome assessments (COAs) differ across the various therapeutic areas?
Mooney: That's a great question. I would say, in general, clinical outcome assessments can benefit just about every therapeutic area in some way. However, we certainly see that there are some therapeutic areas that definitely rely more heavily on the utilization of COAs, and COA strategy to support their protocols, key study objectives, and endpoints. And these are usually therapeutic areas where the disease is known to have a really profound impact on the patient's daily life; how they they're able to go about their daily activities, engage in social situations, and just their overall general well-being is often impacted by the disease. So it makes sense and these types of protocols that the key study objectives and endpoints are usually crafted around how a study treatment impacts the various facets of that patient's life. So we find in these therapeutic areas, that there usually exists a vast number of clinical outcome assessment questionnaires that are intended to measure how that specific disease is impacting the patient's life. So usually in those protocols, COAs are front and center.
To summarize, I would say the utilization of COAs across the therapeutic area or how it differs is really dependent on how that therapeutic area’s protocols use COA strategies to drive their endpoints and objectives. And the utilization tends to be higher in those therapeutic areas where COAs are supporting objectives that are higher in the objective and endpoint hierarchy I'll say.
I can expand on that a little bit more as far as areas where we see a high utilization of COAs, dermatology studies, for example, clearly people who have skin conditions, it's impacting their outward physical appearance often and that takes its toll psychologically, and then, of course that impacts the patient's ability to go about their daily life. So in dermatology studies, we definitely see COAs being front and center and used in abundance in those areas. Same with pain studies. Any area where being able to measure improvements is difficult to do objectively and you really need the voice of the patient. That's also where we see COAs playing a really important role.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5